Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
NEJM Evidence|May 26, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular EvolutionIvan Civettini, Federica Malighetti, Matteo Villa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing AssaysCatherine C Coombs, Nancy K Gillis, Xianming Tan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018Ruben A Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Blood Cancer Discovery|February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsDimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Nature Medicine|February 20, 2018
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancersMichael Seiler, Akihide Yoshimi, Rachel Darman, et al.
Cancer Discovery|August 27, 2024
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal HematopoiesisNana Adjoa Ben-Crentsil, Wazim Mohammed Ismail, Maria E Balasis, et al.
Nature Communications|May 19, 2021
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axisRyan M Carr, Denis Vorobyev, Terra Lasho, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Pageof 21